---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-031423"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-08-05T20:10:51+00:00"
generated_at: "2026-08-05T20:12:39.636328+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)

## Summary
- Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).
- ASCENIV revenue $102.9M (+24% YoY); BIVIGAM revenue $19.4M (-49% YoY but sequential improvement from Q1 2026 trough).
- Gross margin expanded to 69% from 55% YoY, driven by product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing.
- Adjusted EBITDA $61.8M (+22% YoY); FY2026 guidance reiterated: revenue $530-560M, adj. EBITDA $265-300M.
- Repurchased ~7.1M shares in Q2 (13.8M YTD, 5.3% of shares outstanding); SG-001 development on track for pre-IND submission by year-end.

## SEC filing metadata
- accession: 0001140361-26-031423
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-08-05T20:10:51+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/0001140361-26-031423-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-031423
- JSON: https://secwatch.observer/filing/0001140361-26-031423.json
- Plain text: https://secwatch.observer/filing/0001140361-26-031423.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.